BTCY vs. NEPH, MODD, TMDIF, POCI, NMTC, PYPD, COCH, DRIO, FEMY, and OSRH
Should you be buying Biotricity stock or one of its competitors? The main competitors of Biotricity include Nephros (NEPH), Modular Medical (MODD), Titan Medical (TMDIF), Precision Optics (POCI), NeuroOne Medical Technologies (NMTC), PolyPid (PYPD), Envoy Medical (COCH), DarioHealth (DRIO), Femasys (FEMY), and OSR (OSRH). These companies are all part of the "medical equipment" industry.
Biotricity vs. Its Competitors
Nephros (NASDAQ:NEPH) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.
Nephros has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
Nephros has a net margin of 5.16% compared to Biotricity's net margin of -80.42%. Nephros' return on equity of 9.43% beat Biotricity's return on equity.
Nephros presently has a consensus price target of $5.00, suggesting a potential upside of 39.66%. Given Nephros' stronger consensus rating and higher possible upside, analysts clearly believe Nephros is more favorable than Biotricity.
Nephros has higher revenue and earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.
41.1% of Nephros shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 10.1% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Biotricity had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for Biotricity and 1 mentions for Nephros. Biotricity's average media sentiment score of 1.17 beat Nephros' score of 0.93 indicating that Biotricity is being referred to more favorably in the news media.
Summary
Nephros beats Biotricity on 12 of the 16 factors compared between the two stocks.
Get Biotricity News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biotricity Competitors List
Related Companies and Tools
This page (NASDAQ:BTCY) was last updated on 7/18/2025 by MarketBeat.com Staff
Free BTCY Stock Alerts